Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0]

Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C [clinicaltrials:NCT00122616]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir). Week 96 [clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0]

Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0
Bio2RDF identifier
25b97b77ca632addf4fc8705e89353f0
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0
measure [clinicaltrials_vocabulary:measure]
Percentage of patients who exp ...... histological score (Metavir).
time frame [clinicaltrials_vocabulary:time-frame]
description
Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
identifier
clinicaltrials_resource:25b97b77ca632addf4fc8705e89353f0
title
Percentage of patients who exp ...... gical score (Metavir). Week 96
@en
inDataset
type
label
Percentage of patients who exp ...... 97b77ca632addf4fc8705e89353f0]
@en